A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING DOSES OF PF-07304814 ADMINISTERED AS A 24-H IV INFUSION IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 13 Dec 2022
At a glance
- Drugs Lufotrelvir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 01 Dec 2022 Results assessing Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adults published in the Clinical Pharmacology in Drug Development
- 04 Jan 2021 Status changed from recruiting to completed.
- 18 Nov 2020 New trial record